Indians Drop Turkey Travel Plans After Comments Backing Pakistan
Sign up for the India Edition newsletter by Menaka Doshi – an insider's guide to the emerging economic powerhouse, and the billionaires and businesses behind its rise, delivered weekly.
Indians are backing out of trips to Turkey and Azerbaijan, data from travel websites show, after the two nations issued statements supporting Pakistan during heightened conflict between the South Asian rivals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
US Trade Team to Visit India Next Week, Official Says
Sign up for the India Edition newsletter by Menaka Doshi – an insider's guide to the emerging economic powerhouse, and the billionaires and businesses behind its rise, delivered weekly. A team of US officials will visit New Delhi next week as the two nations work to hammer out an interim trade agreement before July 9, an Indian official said on Thursday.
Yahoo
a day ago
- Yahoo
‘They are in shock': Indian students fear Trump has ended their American dream
For weeks, Subash Devatwal's phone has not stopped ringing. Some of the calls have been from distressed students, at other times it is their panicked parents, but all have the same question – is their dream of studying in the US still possible? Devatwal runs an education consultancy in Ahmedabad, the main city in the Indian state of Gujarat. It is one of thousands of such organisations that exist across the country, helping Indian students achieve what many consider to be the ultimate symbol of success: getting into an American university. It has long been a booming business for Devatwal. Families in India will often invest their entire life savings to send their children to study in the US and last year there were more than 330,000 Indians enrolled at American universities, more than any other foreign nationality, overtaking Chinese students in numbers for the first time in years. But this year the situation looks drastically different. As Donald Trump's administration has taken aim at international students – first implementing draconian screening measures over political views and then last week ordering all US embassies globally to indefinitely pause all student visa interviews – many Indian students and their families have been left in limbo. Trump's unilateral decision to block Harvard University from admitting international students, which was later blocked by the courts, also caused widespread panic and stoked fears that foreign students at other universities could get caught in the president's crosshairs. 'The students are in shock. Most of them spend several years preparing to study in the US,' said Devatwal. He said many of his clients were now hesitant to pursue a US degree, given the high levels of turmoil and uncertainty following the Trump administration's new policies. Indian students can expect to pay between $40,000 to $80,000 (£29,500 to £59,000) a year on tuition alone to study in the US. In previous years, Devatwal's organisation sent more than 100 students to American universities but this year he said the number had dropped to about 10. Instead, families were shifting their focus to the UK and other European countries. A recent analysis by the Hindu newspaper estimated a 28% drop in Indian students going to the US in 2025. 'Families contribute their savings, take out loans from banks and borrow from relatives, all in the hope that the student will secure a good job abroad, repay the debt, and build a promising future,' said Devatwal. 'In such uncertain circumstances, parents are understandably reluctant to let their children take such a risky path.' Brijesh Patel, 50, a textile trader in Surat, Gujarat, said he had been saving money for over a decade to make sure his son could go to a US university, including selling his wife's jewellery and borrowing money from relatives. 'Everyone in the family wanted our son to go to the US for his studies and make something good of his life,' said Patel. His 21-year-old son, who he asked not to be named for fear of retribution by the US authorities, had secured a place at two American universities for his master's degree and Patel had already paid 700,000 rupees (£6,000) to consultancies who helped with the applications. But amid the turmoil under Trump, Patel said his son was being advised not to even apply for his student visa, due to the uncertainty and high probability of rejection. 'We simply can't take that risk. If our son goes now and something goes wrong, we won't be able to save that kind of money again,' he said. However, Patel said he was not willing to give up on the family dream just yet. 'I am an optimist, and my son is willing to wait a year,' he said. 'We're hoping that things improve by then. It's not just my son who will be living the American dream, it's all of us: my wife, our relatives and our neighbours. I've struggled my whole life – I don't want my son to face the same struggles here in India.' The fear among prospective and current students was palpable. Several Indian students studying in the US declined to speak to the Guardian, fearing it could jeopardise their visas. In India, a student selected in December to be one of this year's Fulbright-Nehru doctoral fellows – a highly competitive scholarship that pays for the brightest students to study abroad at US universities as part of their PhD thesis – said the applications of their entire cohort had recently been demoted back to 'semi-finalists'. The student, who asked to remain anonymous over fears it would affect their application, said they had invitation letters from top Ivy League universities for the fellowship, which is considered one of the most prestigious scholarships in the US, but now everything was up in the air. 'We are supposed to start in October and our orientation was scheduled for May, all the flights and hotels were even booked, but then it all got cancelled. Now we've been informed all our applications are under review by the Trump administration,' said the student. They said it had caused 'huge panic and anxiety' among those accepted. 'I know a lot of people are going back through their social media, deleting things and doing a lot of self-censoring.' Piyush Bhartiya, a co-founder of the educational technology company AdmitKard, said many parents who had been set on sending their children to the US were rethinking their plans. He cited one example of a student who had been admitted to New York University for the coming year but was instead planning to go to the London School of Economics after the US visa interviews were paused. Bhartiya said Indian students primarily went to the US to study Stem subjects – science, technology, engineering and maths – and so the focus had shifted to other countries strong in these areas. 'Germany is the main country where students are shifting to for Stem subjects,' he said. 'Other countries like Ireland, France, the Netherlands, which are also gaining substantial interest in the students. At the undergraduate level, the Middle East has also seen a lot of gain in interest given parents feel that it is close by and safer and given the current political environment they may want their kids closer to the home.' Among the Indian students forced to abandon their plans is Nihar Gokhale, 36. He had a fully funded offer for a PhD at a private university in Massachusetts, but recently received a letter saying the funding was being withdrawn, as the university faced issues under the Trump administration. 'It was quite shocking. I spoke to people at the university, and they admitted it was an exceptional situation for them too,' said Gokhale. Without the funding, the US was financially 'out of the question' and he said he had an offer from the UK he now intended to take up. 'For at least the next three or four years, I'm not considering the US at all,' he said. • This article was amended on 4 June 2025 to correct a conversion error. An earlier version said that 700,000 rupees was £68,000 instead of saying £6,000.
Yahoo
2 days ago
- Yahoo
Asia-Pacific Pharmaceutical CMO Market Share Analysis, Trends and Growth Forecasts to 2030 Featuring Catalent, Recipharm, Jubilant Life Sciences and More
Key industry drivers include cost advantages in China, 100% FDI in India, and demand for injectable drugs in cancer research Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Pharmaceutical Contract Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025-2030)" report has been added to offering. The Asia-Pacific Pharmaceutical Contract Manufacturing Organization (CMO) Market is poised for remarkable growth, advancing from an estimated USD 59.97 billion in 2025 to a forecasted USD 91.18 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 8.74% during this period. China's competitive edge in the CMO market is underscored by its low labor costs, tax incentives, and advantageous currency valuation, which enable pharmaceutical companies to significantly reduce manufacturing expenses. The country benefits from a workforce trained in Western standards, who are returning amid stringent immigration policies abroad. These dynamics, along with government support, have positioned China as a major pharmaceutical manufacturing hub. India, too, is capitalizing on the burgeoning CMO market, attracting Japanese pharmaceutical investments through favorable foreign direct investment policies. This strategic alignment is fostering partnerships that significantly bolster the domestic manufacturing landscape. Japan's CMO sector, although nascent, has observed a substantial 30% growth following regulatory changes that distinguish manufacturing from sales. Leading players include Bushu Pharmaceuticals and CMIC. Australia's pharmaceuticals face challenges due to pricing and reimbursement volatility, yet its geographical location near South Asian markets enhances its export potential. The COVID-19 pandemic, having originated in Wuhan, a vital pharmaceutical center, has affected global supply chains. This disruption necessitates strategic responses to inventory management, as China provides essential raw materials. Injectable Dose Formulations Lead Growth The demand for injectable drugs, driven by the need for rapid acting oncology treatments, underscores a significant opportunity within the market. These formulations promise higher returns due to therapeutic efficiency and swift action. Prolific late-stage clinical trials, chiefly in cancer therapies, are poised to amplify market growth, with anti-cancer drugs comprising nearly half of the developmental pipeline. Outsourcing of biologic formulations to CMOs is prevalent, as major pharmaceutical entities concentrate on the discovery and development of new drug modalities. India's Impactful CMO Market Share India leverages its vast manpower and regulatory approval to attract multinational pharmaceutical enterprises, enhancing its global footprint in drug manufacturing. Recent policies allowing certain drug studies without late-stage clinical trials lead to considerable cost savings, fortifying India's appeal for pharmaceutical production. The impact of the COVID-19 outbreak on India's sector is evident, with increased costs for APIs due to reliance on Chinese production. The APAC pharmaceutical CMO market shows a highly fragmented landscape. Large pharmaceutical firms are increasingly outsourcing production to CMOs, seeking cost efficiency and expertise. Vendors are expanding through strategic collaborations to enhance market share. Recent industry developments include expansions by Jubilant Biosys in India and Boehringer's capacity increase in China. Key Topics Covered1 INTRODUCTION1.1 Study Assumptions and Market Definition1.2 Scope of the Study2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY4 MARKET DYNAMICS4.1 Market Overview4.2 Industry Attractiveness - Porter's Five Forces Analysis4.3 Industry Value Chain Analysis4.4 Industry Policies4.5 Market Drivers4.5.1 Increasing Outsourcing Volume by Pharmaceutical Companies4.6 Market Restraints4.6.1 Increasing Lead Time and Logistics Costs4.6.2 Stringent Regulatory Requirements4.6.3 Capacity Utilization Issues Affecting the Profitability of CMOs4.7 Assessment of Impact of COVID-19 on the market5 TECHNOLOGY SNAPSHOT6 MARKET SEGMENTATION6.1 Service Type6.1.1 Active Pharmaceutical Ingredient (API) Manufacturing6.1.1.1 Small Molecule6.1.1.2 Large Molecule6.1.1.3 High Potency API (HPAPI)6.1.2 Finished Dosage Formulation (FDF) Development and Manufacturing6.1.2.1 Solid Dose Formulation6.1.2.2 Liquid Dose Formulation6.1.2.3 Injectable Dose Formulation6.1.3 Secondary Packaging6.2 Country6.2.1 China6.2.2 India6.2.3 Japan6.2.4 Australia6.2.5 Rest of Asia-Pacific7 COMPETITIVE LANDSCAPE7.1 Company Profiles7.1.1 Catalent Inc.7.1.2 Recipharm AB7.1.3 Jubilant Life Sciences Ltd.7.1.4 Thermo Fisher Scientific Inc. (Patheon Inc.)7.1.5 Boehringer Ingelheim Group7.1.6 Pfizer CentreSource (Pfizer Inc.)7.1.7 Aenova Group7.1.8 Famar SA7.1.9 Baxter Biopharma Solutions(Baxter International Inc.)7.1.10 Lonza Group8 INVESTMENT ANALYSIS9 FUTURE OF THE MARKET For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
